{"nctId":"NCT01734811","briefTitle":"Efficacy and Safety Evaluation in Recurrent Wheezing Attacks","startDateStruct":{"date":"2012-10"},"conditions":["Bronchospasm; Bronchiolitis","Bronchospasm; Bronchitis"],"count":120,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Biological vaccine"]},{"label":"Biological vaccine","type":"EXPERIMENTAL","interventionNames":["Biological: Biological vaccine"]}],"interventions":[{"name":"Biological vaccine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects whose parents /legal representative have given written informed consent.\n* Both gender\n* Subject up to 36 months of age.\n* Subjects with recurrent bronchospasms (wheezing attacks); 3 or more exacerbations in the last 12 months\n\nExclusion Criteria:\n\n* Subjects whose parents/legal representative have not given written informed consent.\n* Subjects out of aged range\n* Subjects with malignancies or chemotherapy treatment\n* Subjects included in another clinical trial in the last 12 months.\n* Subject in immunosuppressive or immunostimulatory treatment\n* Subjects who have received iv gamma globulin in the past 12 months.\n* Subjects diagnosed with candidiasis or fungal recurrent infections.\n* Subjects diagnosed with malabsorption syndrome\n* Subjects with clinical allergy to common aeroallergens in the geographical area.\n* Subjects with hepatitis virus infections, HIV and tuberculosis","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Months","maximumAge":"36 Months","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Recurrent Bronchospasm (Wheezing Attacks)","description":"Assessment of reduction of bronchospasm (wheezing attacks) episodes at 12 months. The number of bronchospasm (wheezing attacks) episodes, in active and placebo group will be compared","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"299","spread":null},{"groupId":"OG001","value":"176","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration (Days) of Wheezing Attacks (WA)","description":"Review of bronchospasm (wheezing attacks) duration per patient","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.9","spread":null},{"groupId":"OG001","value":"6.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Time Until Appearance of First WA","description":"time (days) until appearance of first wheezing attack (WA)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":null},{"groupId":"OG001","value":"41.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Days With Wheezing Attacks During the Study","description":"Review of the number of days with wheezing attacks during the study","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.0","spread":null},{"groupId":"OG001","value":"19.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Recurrent WA During the Study","description":"Review of number of patients with recurrent WA during the whole study","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"36","spread":null}]}]}]},{"type":"SECONDARY","title":"Symptom Score During Wheezing Attacks","description":"Total of Symptom score during wheezing attacks. The patients were reviewed at our clinics every three months. These scores were recorded daily in a diary card by the parents, who were duly instructed.\n\nScale use to evaluate symptom during wheezing attacks is called the Symptom scores (SS) scale. Minimum value is 0 (meant improvement) and maximum value (meant not improvement) is 3.\n\nThe rating was: 0=absent (no sign/symptom evident); 1=mild (sign/symptom clearly present, but easily tolerated); 2=moderate (definite awareness of sign/symptom that is bothersome but tolerable) and 3=severe (sign/symptom that is hard to tolerate; causes interference with activities of daily life and/or sleeping). Fever was scored as number of days with temperature over 37ºC.\n\nThe total symptom score was calculated as the sum of all individual scores during the wheezing attacks.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"155.0","spread":null},{"groupId":"OG001","value":"80.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Medication Score During WA","description":"Review of medication consumption during wheezing attacks. The patients were reviewed at our clinics every three months. Medication scores were recorded daily in a diary card by the parents, who were duly instructed.\n\nMedication was rated from 0 (minimum value) and the maximum value correspond to the maximum medication consumed per 24h. Rating was according to Dreborg et al. with slight modifications: two points were given for one tablet of 4 mg of Montelukast, for one puff of 50 μg budesonide-equivalent or for one dose of oral prednisolone, and 3 for the inhalation of one puff of 200 μg budesonide-equivalent. In the case of antibiotics and antipyretic/-anti-inflammatory drugs, the number of daily doses of these drugs was recorded.\n\nThe total symptom score was calculated as the sum of all individual scores during the wheezing attacks.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"424.0","spread":null},{"groupId":"OG001","value":"164.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Symptom Score","description":"Review of symptoms during the whole study. The patients were reviewed at our clinics every three months. These scores were recorded daily in a diary card by the parents, who were duly instructed.\n\nScale use to evaluate symptom during wheezing attacks is called the Symptom scores (SS) scale. Minimum value is 0 (meant improvement) and maximum value (meant not improvement) is 3.\n\nThe rating was: 0=absent (no sign/symptom evident); 1=mild (sign/symptom clearly present, but easily tolerated); 2=moderate (definite awareness of sign/symptom that is bothersome but tolerable) and 3=severe (sign/symptom that is hard to tolerate; causes interference with activities of daily life and/or sleeping). Fever was scored as number of days with temperature over 37ºC.\n\nThe total symptom score was calculated as the sum of all individual scores during the whole study","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"421.0","spread":null},{"groupId":"OG001","value":"276.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Medication Score","description":"Review of medication consumption during the whole study. The patients were reviewed at our clinics every three months. Medication scores were recorded daily in a diary card by the parents, who were duly instructed.\n\nMedication was rated from 0 (minimum value) and the maximum value correspond to the maximum medication consumed per 24h. Rating was according to Dreborg et al. with slight modifications: two points were given for one tablet of 4 mg of Montelukast, for one puff of 50 μg budesonide-equivalent or for one dose of oral prednisolone, and 3 for the inhalation of one puff of 200 μg budesonide-equivalent. In the case of antibiotics and antipyretic/-anti-inflammatory drugs, the number of daily doses of these drugs was recorded.\n\nThe total symptom score was calculated as the sum of all individual scores during the whole study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1043.5","spread":null},{"groupId":"OG001","value":"618.5","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Use of Health and Social Resources During the Whole Period of the Study.","description":"The use of health and social resources during the study was also recorded: days of hospitalization in ward and/or intensive care unit, visits to the emergency units, unscheduled visits to the pediatrician and/or to the specialist, telephone calls to the pediatrician, complementary tests (chest radiogram, blood analysis, others), days of school absenteeism and caregiver-days when the children needed them. The data were obtained from the diary cards and confirmed through the review of medical records.\n\nMaximum value corresponds to the maximum days spent in health resources (specified above) and the minimum value corresponds to the minimum of days spent in health resources (specified above)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.5","spread":null},{"groupId":"OG001","value":"11.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":58},"commonTop":[]}}}